Cargando…
Sex Differences in Time to Treat and Outcomes for Gliomas
BACKGROUND: Gliomas are the most common type of primary malignant brain tumor in adults, representing one third of all primary and central nervous system (CNS) tumors and 80% of malignant tumors diagnosed in the Western world. Epidemiological data indicate that the overall incidence and mortality of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933512/ https://www.ncbi.nlm.nih.gov/pubmed/33680971 http://dx.doi.org/10.3389/fonc.2021.630597 |
_version_ | 1783660627562070016 |
---|---|
author | Stabellini, Nickolas Krebs, Halle Patil, Nirav Waite, Kristin Barnholtz-Sloan, Jill S. |
author_facet | Stabellini, Nickolas Krebs, Halle Patil, Nirav Waite, Kristin Barnholtz-Sloan, Jill S. |
author_sort | Stabellini, Nickolas |
collection | PubMed |
description | BACKGROUND: Gliomas are the most common type of primary malignant brain tumor in adults, representing one third of all primary and central nervous system (CNS) tumors and 80% of malignant tumors diagnosed in the Western world. Epidemiological data indicate that the overall incidence and mortality of cancer is higher in males, while females have a better prognosis. The goal of this study is to determine whether there are sex differences in the time to treat and clinical outcomes in patients with glioma METHODS: Glioblastoma (GB) and Lower Grade Glioma (LGG) patients were defined per the Central Brain Tumor Registry of the United States (CBTRUS) from the National Cancer Database (NCDB) for diagnosis years 2004 to 2016. Associations between sex and time to treatment variables as well as associations between sex and multiple clinical outcomes were assessed using univariable and multivariable models. RESULTS: A total of 176,100 patients were used for analysis (124,502 GBM and 51,598 LGG). Males had a statistically significant association with >7 days to surgery (OR = 1.09, CI 1.05–1.13, p < 0.001) but this association was not observed in the multivariable model (OR = 1.05, CI 0.96–1.16, p = 0.25). After adjustment for key variables including time to treat variables, males with GB and LGG had a higher risk of death (HR = 1.11, CI 1.09–1.13, p < 0.001, HR = 1.09, CI 1.03–1.15, p < 0.001; respectfully). Sex differences in 90-day mortality for GBM were not found after adjustment (OR for males = 0.99, CI 0.91–1.08, p = 0.93). For LGG, both the univariable and multivariable logistic regression models showed no sex differences in 90-day mortality (OR for males = 1.03, CI 0.94–1.12, p = 0.45; multivariable OR for males = 0.81, CI 0.62–1.06, p = 0.13). CONCLUSIONS: Based on NCDB data, there were no statistically significant differences in time to treatment between males and females, however males had a higher proportion of GB and LGG as well as a higher risk of death compared to females. |
format | Online Article Text |
id | pubmed-7933512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79335122021-03-06 Sex Differences in Time to Treat and Outcomes for Gliomas Stabellini, Nickolas Krebs, Halle Patil, Nirav Waite, Kristin Barnholtz-Sloan, Jill S. Front Oncol Oncology BACKGROUND: Gliomas are the most common type of primary malignant brain tumor in adults, representing one third of all primary and central nervous system (CNS) tumors and 80% of malignant tumors diagnosed in the Western world. Epidemiological data indicate that the overall incidence and mortality of cancer is higher in males, while females have a better prognosis. The goal of this study is to determine whether there are sex differences in the time to treat and clinical outcomes in patients with glioma METHODS: Glioblastoma (GB) and Lower Grade Glioma (LGG) patients were defined per the Central Brain Tumor Registry of the United States (CBTRUS) from the National Cancer Database (NCDB) for diagnosis years 2004 to 2016. Associations between sex and time to treatment variables as well as associations between sex and multiple clinical outcomes were assessed using univariable and multivariable models. RESULTS: A total of 176,100 patients were used for analysis (124,502 GBM and 51,598 LGG). Males had a statistically significant association with >7 days to surgery (OR = 1.09, CI 1.05–1.13, p < 0.001) but this association was not observed in the multivariable model (OR = 1.05, CI 0.96–1.16, p = 0.25). After adjustment for key variables including time to treat variables, males with GB and LGG had a higher risk of death (HR = 1.11, CI 1.09–1.13, p < 0.001, HR = 1.09, CI 1.03–1.15, p < 0.001; respectfully). Sex differences in 90-day mortality for GBM were not found after adjustment (OR for males = 0.99, CI 0.91–1.08, p = 0.93). For LGG, both the univariable and multivariable logistic regression models showed no sex differences in 90-day mortality (OR for males = 1.03, CI 0.94–1.12, p = 0.45; multivariable OR for males = 0.81, CI 0.62–1.06, p = 0.13). CONCLUSIONS: Based on NCDB data, there were no statistically significant differences in time to treatment between males and females, however males had a higher proportion of GB and LGG as well as a higher risk of death compared to females. Frontiers Media S.A. 2021-02-19 /pmc/articles/PMC7933512/ /pubmed/33680971 http://dx.doi.org/10.3389/fonc.2021.630597 Text en Copyright © 2021 Stabellini, Krebs, Patil, Waite and Barnholtz-Sloan http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Stabellini, Nickolas Krebs, Halle Patil, Nirav Waite, Kristin Barnholtz-Sloan, Jill S. Sex Differences in Time to Treat and Outcomes for Gliomas |
title | Sex Differences in Time to Treat and Outcomes for Gliomas |
title_full | Sex Differences in Time to Treat and Outcomes for Gliomas |
title_fullStr | Sex Differences in Time to Treat and Outcomes for Gliomas |
title_full_unstemmed | Sex Differences in Time to Treat and Outcomes for Gliomas |
title_short | Sex Differences in Time to Treat and Outcomes for Gliomas |
title_sort | sex differences in time to treat and outcomes for gliomas |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933512/ https://www.ncbi.nlm.nih.gov/pubmed/33680971 http://dx.doi.org/10.3389/fonc.2021.630597 |
work_keys_str_mv | AT stabellininickolas sexdifferencesintimetotreatandoutcomesforgliomas AT krebshalle sexdifferencesintimetotreatandoutcomesforgliomas AT patilnirav sexdifferencesintimetotreatandoutcomesforgliomas AT waitekristin sexdifferencesintimetotreatandoutcomesforgliomas AT barnholtzsloanjills sexdifferencesintimetotreatandoutcomesforgliomas |